FDA Warns Clinics About New Bogus Batches Of Avastin

Law360, New York (February 6, 2013, 6:43 PM EST) -- The U.S. Food and Drug Administration on Tuesday warned health care providers that it had discovered batches of a product posing as blockbuster cancer treatment Avastin sold by a New York-based distributor were counterfeit, the third such warning involving the drug in a year.

The fake drugs are labeled as Altuzan, Roche Holding AG’s trade name for Avastin in Turkey, and FDA laboratory tests have shown the purported Altuzan vials contain no bevacizumab, the active ingredient in Avastin, according to a statement by the agency....
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.